Learn about all myeloma happenings on the new Myeloma Crowd site: the first comprehensive site for myeloma patients and caregivers. Dr. Jonathan Licht, MD Northwestern University Robert H. Lurie Comprehensive Cancer Center Interview date: April 11, 2014
Dr. Licht shares a deep dive into high risk myeloma with an emphasis on the 4;14 mutation that triggers the overproliferation of the MMSET gene. Dr. Licht describes how MMSET affects the cells and his work to screen 100,000 compounds against that gene to find targets that impact MMSET effectively. He describes the relationship between the MMSET and MYC genes and how MMSET promotes MYC growth. He shares how cell signaling pathway treatments, like MEK inhibitors and BRAF inhibitors are being studied to change the signaling for cancer growth for high risk and normal risk myeloma as well. The live mPatient Myeloma Radio podcast with Dr. Jonathan Licht
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113